DelveInsight's Triple-Negative Breast Cancer Market Insights report includes a comprehensive understanding of current treatment practices, triple-negative breast cancer emerging drugs, market share of ...

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved diagnostics ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

Biotech giant Bristol-Myers Squibb Company (BMY) is scheduled to report second-quarter 2025 results on July 31, before market ...

Bristol Myers is making waves after a period of pressure. The stock jumped 6.3% recently, outperforming its industry and the ...

Bristol Myers (BMY) delivered an impressive performance in the past month after being under pressure for quite some time. The ...

Sotyktu (deucravacitinib) has been assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 6, 2026.

Bristol Myers Squibb BMY announced a strategic collaboration agreement with BioNTech BNTX for the global co-development and ...

Last week, BMY announced a strategic collaboration agreement with BioNTech BNTX for the global co-development and co-commercialization of BioNTech’s investigational bispecific antibody BNT327 ...

A novel bispecific antibody, BNT327/PM8002, shows promising efficacy in treating unresectable mesothelioma, combining well with chemotherapy for durable responses.

BioNTech SE and Bristol Myers Squibb announced that the companies have entered into an agreement for the global co-development and co-commercialization of BioNTech’s investigational bispecific ...